Abstract: A multilayered drug delivery system with a barrier suitable for delivery of drug through an individual's body surface. By placing a barrier between two adjacent layers, unintended drug flow due to migration of a drug matrix between the adjacent matrix layers in the system to a patient is avoided.
Abstract: A device (12) and method are provided for percutaneous transdermal delivery of a potent pharmacologically active agent. The agent is dissolved in water to form an aqueous coating solution having an appropriate viscosity for coating extremely tiny skin piercing elements (10). The coating solution is applied to the skin piercing elements (10) using known coating techniques and then dried. The device (12) is applied to the skin of a living animal (e.g., a human), causing the microprotrusions (10) to pierce the stratum corneum and deliver a therapeutically effect dose of the agent to the animal.
Type:
Grant
Filed:
February 2, 2006
Date of Patent:
March 4, 2014
Assignee:
Alza Corporation
Inventors:
Michel J. N. Cormier, Wendy A. Young, Kofi Nyam, Peter E. Daddona, Wei-Qi Lin
Abstract: Sustained release dosage forms for twice daily oral dosing to a human patient for providing relief from pain are provided. The sustained release dosage form comprises an immediate release component and a sustained release component, wherein the immediate release component and the sustained release component collectively contain a therapeutically effective amount of an opioid analgesic and a therapeutically effective amount of nonopioid analgesic. In a preferred embodiment, the nonopioid analgesic is acetaminophen and the opioid analgesic is hydrocodone and pharmaceutically acceptable salts thereof, and in preferred embodiments, the pharmaceutically acceptable salt is bitartrate. The dosage forms produce plasma profiles in a patient characterized by a Cmax for hydrocodone of between about 0.6 ng/mL/mg to about 1.4 ng/mL/mg and an AUC for hydrocodone of between about 9.1 ng*hr/mL/mg to about 19.9 ng*hr/mL/mg (per mg hydrocodone bitartrate administered) and a Cmax for acetaminophen of between about 2.
Type:
Application
Filed:
October 21, 2013
Publication date:
February 13, 2014
Applicant:
ALZA CORPORATION
Inventors:
Evangeline Cruz, Atul D. Ayer, Brenda J. Pollock, Carmelita Garcia, Sherry Li, Alfredo M. Wong, Lawrence G. Hamel, Cheri Enders Klein, Yihong Qiu, Ye Huang
Abstract: A method and a non-rate controlled, monolithic, subsaturated patch for transdermally administering fentanyl and analogs thereof, for analgetic purposes, to a subject through skin over an extended period of time are disclosed.
Type:
Application
Filed:
July 11, 2013
Publication date:
January 30, 2014
Applicant:
ALZA Corporation
Inventors:
Subramanian S. Venkatraman, Shaoling Li, Robert M. Gale, Jane Stepic, William W. Van Osdol
Abstract: A multilayered drug delivery system with a barrier suitable for delivery of drug through an individual's body surface. By placing a barrier between two adjacent layers, unintended drug flow due to migration of a drug matrix between the adjacent matrix layers in the system to a patient is avoided.
Abstract: An apparatus and method for transdermally delivering a biologically active agent comprising a delivery system having a microprojection member (or system) that includes a plurality of microprojections (or array thereof) that are adapted to pierce through the stratum corneum into the underlying epidermis layer, or epidermis and dermis layers. In one embodiment, the PTH-based agent is contained in a biocompatible coating that is applied to the microprojection member.
Type:
Grant
Filed:
March 2, 2010
Date of Patent:
January 21, 2014
Assignee:
Alza Corporation
Inventors:
Mahmoud Ameri, Michel J. N. Cormier, Yuh-Fun Maa, Marika Kamberi, Peter E. Daddona
Abstract: Compositions of and methods for formulating and delivering biologically active agent formulations having enhanced physical stability, and wherein deterioration from the presence of oxygen and/or water is minimized and/or controlled, to yield a stable formulation. The compositions of and methods for formulating and delivering biologically active agents of the present invention further facilitate their incorporation into a biocompatible coating which can be employed to coat a stratum-corneum piercing microprojection, or a plurality of stratum-corneum piercing microprojections of a delivery device, for delivery of the biocompatible coating through the skin of a subject, thus providing an effective means of delivering the biologically active agents.
Type:
Grant
Filed:
December 28, 2006
Date of Patent:
January 21, 2014
Assignee:
Alza Corporation
Inventors:
Mahmoud Ameri, Michel J. N. Cormier, Scott Sellers, Yuh-Fun Maa
Abstract: Methods and devices for maintaining a desired therapeutic drug effect over a prolonged therapy period are provided. In particular, oral dosage forms that release drug within the gastrointestinal tract at an ascending release rate over an extended time period are provided. The dosage forms may additionally comprise an immediate-release dose of drug.
Type:
Grant
Filed:
October 19, 2009
Date of Patent:
January 14, 2014
Assignee:
Alza Corporation
Inventors:
Suneel K. Gupta, Diane R. Guinta, Carol A. Christopher, Samuel R. Saks, Lawrence G. Hamel
Abstract: A method for making a jet injection drug delivery device wherein the drug delivery device has at least one drug reservoir and at least one injection nozzle includes the steps of: identifying a drug desired to be delivered; identifying a volume of the drug desired to be delivered; establishing a reservoir diameter for the at least one drug reservoir; establishing a nozzle diameter for the at least one injection nozzle; identifying a tissue model for delivery of the drug; identifying a penetration depth in the tissue model for the delivery of the drug; and injecting the drug into the tissue model under variable pressure until the desired penetration depth is achieved. The method also includes identifying an optimal pressure range for the drug delivery device that achieves the desired penetration depth.
Abstract: The present invention relates to a novel controlled release formulations of tizanidine. The invention also provides methods of using novel controlled release formulations of tizanidine to treat a patient.
Abstract: A membrane system comprising an interior wall, a fluid-permeable exterior wall surrounding the interior wall and an internal compartment defined by the membrane system, wherein fluid permeability of the interior wall is responsive to osmolarity of an osmotic core within the internal compartment are disclosed. A controlled release dosage form comprising the membrane system and a process for delivering an osmotically active formulation from an osmotic pump over an extended period of time are also disclosed.
Type:
Grant
Filed:
February 9, 2007
Date of Patent:
September 3, 2013
Assignee:
Alza Corporation
Inventors:
David E. Edgren, Patrick S.-L. Wong, Gurdish K. Bhatti, Shu Li, Robert R. Skluzacek
Abstract: Methods and devices for maintaining a desired therapeutic drug effect over a prolonged therapy period are provided. In particular, oral dosage forms that release drug within the gastrointestinal tract at an ascending release rate over an extended time period are provided. The dosage forms may additionally comprise an immediate-release dose of drug.
Abstract: Sustained release dosage forms for twice daily oral dosing to a human patient for providing relief from pain are provided. The sustained release dosage form comprises an immediate release component and a sustained release component, wherein the immediate release component and the sustained release component collectively contain a therapeutically effective amount of an opioid analgesic and a therapeutically effective amount of nonopioid analgesic. In a preferred embodiment, the nonopioid analgesic is acetaminophen and the opioid analgesic is hydrocodone and pharmaceutically acceptable salts thereof, and in preferred embodiments, the pharmaceutically acceptable salt is bitartrate. The dosage forms produce plasma profiles in a patient characterized by a Cmax for hydrocodone of between about 0.6 ng/mL/mg to about 1.4 ng/mL/mg and an AUC for hydrocodone of between about 9.1 ng*hr/mL/mg to about 19.9 ng*hr/mL/mg (per mg hydrocodone bitartrate administered) and a Cmax for acetaminophen of between about 2.
Abstract: Methods and devices for maintaining a desired therapeutic drug effect over a prolonged therapy period are provided. In particular, oral dosage forms that release drug within the gastrointestinal tract at an ascending release rate over an extended time period are provided. The dosage forms may additionally comprise an immediate-release dose of drug.
Abstract: A polyacrylate formulation suitable for delivery of drug to through a body surface of an individual. By loading the drug and permeation enhancers at a high concentration into a polyacrylate proadhesive that has inadequate adhesive properties for typical adhesive application on the skin, a formulation with desirable adhesive characteristics and effective therapeutic properties can be made. The proadhesive has higher glass transition temperature than typical pressure sensitive adhesives.
Abstract: Devices, systems and methods for controlling the application of current and/or voltage to deliver drug from patient contacts of an electrotransport drug delivery device by indirectly controlling and/or monitoring the applied current without directly measuring from the cathode of the patient terminal. In particular, described herein are electrotransport drug delivery systems including constant current delivery systems having a feedback current and/or voltage control module that is isolated from the patient contacts (e.g., anodes and cathodes). The feedback module may be isolated by a transistor from the patient contacts; feedback current and/or voltage control measurements may be performed at the transistor rather than at the patient contact (e.g., cathode).
Abstract: Electrotransport drug delivery devices, system and methods of using configured to determine if a current is present between the anode and cathode when drug is not intended to be delivered by the device. These devices/systems may include an off-current module to determine that any current (e.g., which may be inferred by measuring potential difference between the anode and cathode of the device) flowing between the anode and cathode is below a threshold value when the device is not supposed to be delivering drug, thereby preventing unintended delivery of drug and/or alerting a user that unintended delivery of drug may occur.
Abstract: A polyacrylate formulation suitable for delivery of drug through a body surface of an individual. By loading the drug and permeation enhancers at a high concentration into a polyacrylate proadhesive that has inadequate adhesive properties for typical adhesive application on the skin, a formulation with desirable adhesive characteristics and effective therapeutic properties can be made. The proadhesive has higher glass transition temperature than typical pressure sensitive adhesives.
Type:
Grant
Filed:
September 22, 2006
Date of Patent:
February 26, 2013
Assignee:
ALZA Corporation
Inventors:
Jay Audett, Jianye Wen, Eli J. Goldman, Robert M. Gale, Allison Luciano, Paul B. Foreman, Eric N. Silverberg
Abstract: The invention disclosed comprises a method for administering the antidiabetic drug glipizide to a patient in need of glipizide in need of antidiabetic therapy.
Type:
Grant
Filed:
March 2, 2012
Date of Patent:
August 27, 2013
Assignee:
Alza Corporation
Inventors:
Anthony L. Kuczynski, Atul Devdatt Ayer, Patrick S. L. Wong